Sign In
Buy IVBXF
$10.24
-0.190 (-1.83%)
At Close: Jun 03, 2026
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:00pm, Sunday, 05'th Jan 2025
SAN FRANCISCO and SUZHOU, China , Jan. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
SAN FRANCISCO and SUZHOU, China , Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ
SAN FRANCISCO, U.S. and SUZHOU, China , Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and comme
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
11:05pm, Wednesday, 27'th Nov 2024
SAN FRANCISCO and SUZHOU, China , Nov. 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
07:23pm, Sunday, 24'th Nov 2024
SAN FRANCISCO and SUZHOU, China , Nov. 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
Claudin18.2-targeting therapy market is expected to increase further, owing to the encouraging results of current medications and a growing pipeline. While G/GEJ malignancies remain the primary focus,
SAN FRANCISCO and SUZHOU, China , Oct. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
08:00pm, Wednesday, 16'th Oct 2024
SAN FRANCISCO and SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
SAN FRANCISCO and SUZHOU, China , Oct. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ
Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis
12:15am, Thursday, 26'th Sep 2024
SAN FRANCISCO and SUZHOU, China , Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
SAN FRANCISCO and SUZHOU, China , Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
SAN FRANCISCO and SUZHOU, China , Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
SAN FRANCISCO and SUZHOU, China , Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ
SAN FRANCISCO and SUZHOU, China , Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia
SAN FRANCISCO and SUZHOU, China , Sept. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
